Lyell Immunopharma, Inc. Common Stock (LYEL) Stock Price

LYELStock

$15.49+36.99%52W

Market Cap$379.58M

P/E—

PEG Ratio—

Div yield—

Beta-0.05

LYEL Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-50.81%

Price vs S&P 500 (4W)10.42%

VGM Score29.64

Book Value / Share (Quarterly)$11.73

P/TBV (Annual)0.51x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-92.48%

Cash Flow / Share (Quarterly)$-7.53

Price vs S&P 500 (YTD)-64.07%

Net Profit Margin (TTM)-794858.06%

EPS (TTM)$-12.98

10-Day Avg Trading Volume0.14M

EPS Excl Extra (TTM)$-12.98

Revenue Growth (5Y)-65.86%

EPS (Annual)$-16.06

ROI (Annual)-110.57%

Net Profit Margin (5Y Avg)-301538.54%

Cash / Share (Quarterly)$10.89

Revenue Growth QoQ (YoY)-71.43%

ROA (Last FY)-80.71%

Revenue Growth TTM (YoY)-52.31%

EBITD / Share (TTM)$-12.98

ROE (5Y Avg)-56.98%

Operating Margin (TTM)-823341.94%

Cash Flow / Share (Annual)$-9.03

P/B Ratio1.23x

P/B Ratio (Quarterly)1.71x

Net Income / Employee (Annual)$-1,704,600

EV / Revenue (TTM)7933.25x

ROA (TTM)-66.41%

EPS Incl Extra (Annual)$-16.06

Current Ratio (Annual)5.28x

Quick Ratio (Quarterly)6.88x

3-Month Avg Trading Volume0.15M

52-Week Price Return36.99%

Revenue / Employee (TTM)$200

Tangible BV / Share (Quarterly)$2.77

P/S Ratio (Annual)9352.80x

Asset Turnover (Annual)0.00x

52-Week High$45.00

Operating Margin (5Y Avg)-312062.62%

EPS Excl Extra (Annual)$-16.06

CapEx CAGR (5Y)-4.00%

26-Week Price Return-39.57%

Quick Ratio (Annual)5.00x

13-Week Price Return-14.80%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)7.23x

Enterprise Value$245.93M

Revenue / Share Growth (5Y)-42.00%

Asset Turnover (TTM)0.00x

Revenue / Employee (Annual)$200

Pretax Margin (Annual)-762355.56%

Cash / Share (Annual)$11.63

3-Month Return Std Dev88.81%

Net Income / Employee (TTM)$-1,530,500

ROE (Last FY)-110.57%

EPS Basic Excl Extra (Annual)$-16.06

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-12.98

ROI (TTM)-85.71%

P/S Ratio (TTM)10861.31x

Pretax Margin (5Y Avg)-301538.54%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$3.34

Price vs S&P 500 (52W)18.68%

Year-to-Date Return-52.11%

5-Day Price Return-6.65%

EPS Normalized (Annual)$-16.06

ROA (5Y Avg)-44.72%

Net Profit Margin (Annual)-762355.56%

Month-to-Date Return13.91%

Cash Flow / Share (TTM)$-0.67

EBITD / Share (Annual)$-15.09

Operating Margin (Annual)-748344.44%

ROI (5Y Avg)-56.98%

EPS Basic Excl Extra (TTM)$-12.98

P/TBV (Quarterly)0.61x

P/B Ratio (Annual)2.63x

Pretax Margin (TTM)-794858.06%

Book Value / Share (Annual)$11.68

Price vs S&P 500 (13W)-17.59%

Beta-0.05x

P/FCF (Annual)14.38x

Revenue / Share (TTM)$0.00

ROE (TTM)-85.71%

52-Week Low$10.50

vGradeD

gGradeF

mGradeC

vgmGradeD

LYEL Earnings Surprise History

Q2 25-2.89est. -3.58

Q3 25-2.13est. -2.64

Q4 25-7.68est. -2.23

Q1 26-1.10est. -2.36

Q2 26-1.74est. -1.79

LYEL Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

3.91

4.00

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
LYELLyell Immunopharma, Inc. Common Stock	D	F	C	$15.49
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Lyell Immunopharma, Inc. Common Stock

Lyell Immunopharma is a clinical-stage cell therapy company developing T-cell therapies for solid tumors through proprietary ex vivo genetic and epigenetic reprogramming technology. The company's pipeline includes three lead candidates: LYL797, LYL119, and LYL845.